Advertisement

Alcohol Use and Antiretroviral Therapy Non-Adherence Among Adults Living with HIV/AIDS in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

  • Jennifer VellozaEmail author
  • Christopher G. Kemp
  • Frances M. Aunon
  • Megan K. Ramaiya
  • Emma Creegan
  • Jane M. Simoni
Substantive Review
  • 39 Downloads

Abstract

Antiretroviral therapy (ART) is efficacious in improving clinical outcomes among people living with HIV (PLWH) and reducing HIV transmission when taken regularly. Research examining modifiable factors associated with ART non-adherence is critical for informing novel intervention development in settings with high HIV prevalence. Alcohol use has been linked with ART non-adherence in studies in sub-Saharan Africa; however, no review has pooled estimates across studies. We reviewed studies of alcohol use and ART non-adherence conducted in sub-Saharan Africa. We searched PubMed, CINAHL, EMBASE, and PsycINFO through August 2019 with terms related to ART non-adherence, alcohol use, and sub-Saharan Africa. One author reviewed titles/abstracts (n = 754) and two authors reviewed full texts (n = 308) for inclusion. Discrepancies were resolved by group consensus. Studies were retained if they quantitatively measured associations between alcohol use and ART non-adherence or viral non-suppression. We defined ART non-adherence using the definitions from each parent study (e.g., patients with > 5% missed ART doses during the previous four, seven or 30 days were considered non-adherent). A random effects meta-analysis was conducted to pool associations and we conducted additional analyses to assess between-study heterogeneity and publication bias and sensitivity analyses to determine robustness of our results when considering only certain study designs, alcohol use or ART scales, or studies that used viral non-suppression as their primary outcome. Of 56 articles meeting our inclusion criteria, 32 articles were included in the meta-analysis. All studies measured alcohol use via self-report. ART non-adherence was assessed using self-report, pill counts, or pharmacy records and definition of non-adherence varied depending on the measure used. Individuals who used alcohol had twice the odds of ART non-adherence compared with those who did not use alcohol (34% non-adherence among alcohol users vs. 18% among non-users; pooled odds ratio: 2.25; 95% confidence interval: 1.87–2.69; p < 0.001). We found evidence of a high degree of heterogeneity between studies (Cochrane Q statistic: 382.84, p< 0.001; I2 proportion: 91.9%) and evidence of publication bias. However, the magnitude of our pooled odds ratio was consistent across a number of sensitivity analyses to account for heterogeneity and publication bias. In a secondary analysis with studies using viral non-suppression as their primary outcome, we also estimated a statistically significant pooled effect of alcohol use on viral non-suppression (pooled odds ratio: 2.47; 95% confidence interval: 1.58–3.87). Evidence suggests alcohol use is associated with ART non-adherence in Sub-Saharan Africa, potentially hindering achievement of the UNAIDS 90-90-90 HIV treatment targets.

Keywords

Alcohol HIV ART adherence Africa Systematic review 

Notes

Acknowledgments

We are grateful for the dedication of the thousands of individuals who have participated in ART clinical trials and adherence studies around the world.

Funding

JV is supported by the National Institute of Mental Health of the US National Institutes of Health (F31 MH113420). CK is supported by a grant from the National Institute of Mental Health (F31 MH112397-01A1). FMA is supported by a grant from the National Institute of Allergy and Infectious Diseases (T32 AI07140). JMS is supported by P30 AI027757. The results and interpretation presented here do not necessarily reflect the views of the study funders.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed were in accordance with the ethical standards of the University of Washington institutional review board, national research ethics committees for the study site, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

10461_2019_2716_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Joint United Nations Programme on HIV/AIDS (2014) UNAIDS report on the global AIDS epidemic 2013. UNAIDS, GenevaGoogle Scholar
  2. 2.
    Joint United Nations Programme on HIV/AIDS (2014) Fast track: ending the AIDS epidemic by 2030. UNAIDS, Geneva. Available from: http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
  3. 3.
    Joint United Nations Programme on HIV/AIDS (2014) 90-90-90: an ambitious treatment target to help end the AIDS epidemic. UNAIDS, GenevaGoogle Scholar
  4. 4.
    Baggaley R, Dalal S, Johnson C, et al. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response. J Int AIDS Soc. 2016;19(1):21348.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review. AIDS Care. 2015;27(7):805–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Hahn JA, Woolf-King SE, Muyindike W. Adding fuel to the fire: alcohol’s effect on the HIV epidemic in Sub-Saharan Africa. Curr HIV/AIDS Rep. 2011;8(3):172–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Nakimuli-Mpungu E, Bass JK, Alexandre P, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav. 2012;16(8):2101–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Heestermans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. BMJ Glob Health. 2016;1(4):e000125.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kalichman SC, Grebler T, Amaral CM, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Braithwaite RS, Conigliaro J, McGinnis KA, Maisto SA, Bryant K, Justice AC. Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. Alcohol Clin Exp Res. 2008;32(9):1645–51.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cook RL, Zhou Z, Kelso-Chichetto NE, et al. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study. Addict Sci Clin Pract. 2017;12(1):22.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Barai N, Monroe A, Lesko C, et al. The association between changes in alcohol use and changes in antiretroviral therapy adherence and viral suppression among women living with HIV. AIDS Behav. 2017;21(7):1836–45.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rehm J, Parry CD. Alcohol consumption and infectious diseases in South Africa. Lancet. 2009;374(9707):2053.CrossRefPubMedGoogle Scholar
  17. 17.
    Neuman MG, Schneider M, Nanau RM, Parry C. Alcohol consumption, progression of disease and other comorbidities, and responses to antiretroviral medication in people living with HIV. AIDS Res Treat. 2012;2012:751827.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal considerations on alcohol and HIV/AIDS: a systematic review. Alcohol. 2010;45(2):159–66.CrossRefGoogle Scholar
  20. 20.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefGoogle Scholar
  21. 21.
    Adeniyi O, Ajayi A, Ter GD, Owolabi EO, Eboh A, Lambert J. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. BMC Infect Dis. 2018;18(1):175.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Alemu H, Haile Mariam D, Tsui AO, Shewamare A. Correlates of highly active antiretroviral therapy adherence among urban Ethiopian clients. Afr J AIDS Res AJAR. 2011;10(3):263–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18(11):1007–15.CrossRefPubMedGoogle Scholar
  24. 24.
    Bezabhe WM, Chalmers L, Bereznicki LR, Gee P, Peterson GM. Antiretroviral adherence and treatment outcomes among adult Ethiopian patients. AIDS Care. 2016;28(8):1018–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Boyer S, Clerc I, Bonono C-R, Marcellin F, Bilé P-C, Ventelou B. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc Sci Med. 2011;72(8):1383–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Bultum JA, Yigzaw N, Demeke W, Alemayehu M. Alcohol use disorder and associated factors among human immunodeficiency virus infected patients attending antiretroviral therapy clinic at Bishoftu General Hospital, Oromiya region, Ethiopia. PLoS ONE. 2018;13(3):e0189312.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cagle A, McGrath C, Richardson BA, et al. Alcohol use and immune reconstitution among HIV-infected patients on antiretroviral therapy in Nairobi, Kenya. AIDS Care. 2017;29(9):1192–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cerutti B, Broers B, Masetsibi M, et al. Alcohol use and depression: link with adherence and viral suppression in adult patients on antiretroviral therapy in rural Lesotho, Southern Africa: a cross-sectional study. BMC Public Health. 2016;16:947.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cichowitz C, Maraba N, Hamilton R, Charalambous S, Hoffmann CJ. Depression and alcohol use disorder at antiretroviral therapy initiation led to disengagement from care in South Africa. PLoS ONE. 2017;12(12):e0189820.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dahab M, Charalambous S, Karstaedt AS, et al. Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health. 2010;10:430.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Denison JA, Koole O, Tsui S, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015;29(3):361–71.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Do NT, Phiri K, Bussmann H, Gaolathe T, Marlink RG, Wester CW. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res Hum Retrovir. 2010;26(6):685–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PloS ONE. 2013;8(1):e53586.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Etienne M, Hossain M, Redfield R, Stafford K, Amoroso A. indicators of adherence to antiretroviral therapy treatment among HIV/AIDS patients in 5 African countries. J Int Assoc Phys AIDS Care JIAPAC. 2010;9(2):98–103.Google Scholar
  35. 35.
    Falang KD, Akubaka P, Jimam NS. Patient factors impacting antiretroviral drug adherence in a Nigerian tertiary hospital. J Pharmacol Pharmacother. 2012;3(2):138–42.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Farley J, Miller E, Zamani A, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Phys AIDS Care. 2010;9(4):218–26.CrossRefGoogle Scholar
  37. 37.
    Fatch R, Emenyonu NI, Muyindike W, Kekibiina A, Woolf-King S, Hahn JA. Alcohol Interactive toxicity beliefs and ART non-adherence among HIV-infected current drinkers in Mbarara, Uganda. AIDS Behav. 2017;21(7):1812–24.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Goar SG, Audu MD, Agbir MT, Matawal B. Substance abuse and adherence to antiretroviral therapy among patients attending clinic at a specialist hospital in Jos, Nigeria. Afr J Drug Alcohol Stud. 2015;14(1):37–47.Google Scholar
  39. 39.
    Gross R, Bellamy SL, Ratshaa B, et al. Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study. Addiction. 2017;112(1):73–81.CrossRefPubMedGoogle Scholar
  40. 40.
    Guira O, Kaboré DSR, Dao G, et al. The modalities of nonadherence to highly active antiretroviral therapy and the associated factors related to patients’ sociodemographic characteristics and their caregiving perceptions in Ouagadougou (Burkina Faso). J Int Assoc Provid AIDS Care. 2016;15(3):256–60.CrossRefPubMedGoogle Scholar
  41. 41.
    Haberer JE, Bwana BM, Orrell C, et al. ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa. J Int AIDS Soc. 2019;22(2):e25232.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hicham T, Ilyas E, Tarik H, et al. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco. Int J Mycobacteriol. 2019;8(2):113–7.PubMedGoogle Scholar
  43. 43.
    Idindil B, Jullu B, Mugusi F, Tanner M. A case-control study of factors associated with non-adherent to antiretroviral therapy among HIV infected people in Pwani Region, eastern Tanzania. Tanzan J Health Res. 2012;14(3):194–203.PubMedGoogle Scholar
  44. 44.
    Jaquet A, Ekouevi DK, Bashi J, et al. Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction. 2010;105(8):1416–21.CrossRefPubMedGoogle Scholar
  45. 45.
    Kader R, Govender R, Seedat S, Koch JR, Parry C. Understanding the impact of hazardous and harmful use of alcohol and/or other drugs on ARV adherence and disease progression. PloS ONE. 2015;10(5):e0125088.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kalichman S, Mathews C, Banas E, Kalichman M. Alcohol-related intentional nonadherence to antiretroviral therapy among people living with HIV, Cape Town, South Africa. AIDS Care. 2019;31(8):951–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Kalichman S, Mathews C, Banas E, Kalichman M. Treatment adherence in HIV stigmatized environments in South Africa: stigma avoidance and medication management. Int J STD AIDS. 2018;30(4):362–70.CrossRefPubMedGoogle Scholar
  48. 48.
    Kazooba P, Mayanja BN, Levin J, Masiira B, Kaleebu P. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy-evidence from a prospective cohort study in rural South-Western Uganda, 2004–2011. Pan Afr Med J. 2018;29:191.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kekwaletswe CT, Jordaan E, Nkosi S, Morojele NK. Social support and the mediating roles of alcohol use and adherence self-efficacy on antiretroviral therapy (ART) adherence among ART recipients in Gauteng, South Africa. AIDS Behav. 2017;21(7):1846–56.CrossRefPubMedGoogle Scholar
  50. 50.
    Kekwaletswe CT, Morojele NK. Patterns and predictors of antiretroviral therapy use among alcohol drinkers at HIV clinics in Tshwane, South Africa. AIDS Care. 2014;26(Suppl 1):S78–82.CrossRefPubMedGoogle Scholar
  51. 51.
    Lancaster KE, Lungu T, Mmodzi P, et al. The association between substance use and sub-optimal HIV treatment engagement among HIV-infected female sex workers in Lilongwe, Malawi. AIDS Care. 2017;29(2):197–203.CrossRefPubMedGoogle Scholar
  52. 52.
    Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS Patient Care STDs. 2014;28(2):98–105.CrossRefPubMedGoogle Scholar
  53. 53.
    Magidson JF, Saal W, Nel A, Remmert JE, Kagee A. Relationship between depressive symptoms, alcohol use, and antiretroviral therapy adherence among HIV-infected, clinic-attending patients in South Africa. J Health Psychol. 2017;22(11):1426–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Marcellin F, Boyer S, Protopopescu C, et al. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116). Trop Med Int Health. 2008;13(12):1470–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Méda ZC, Lin YT, Sombié I, Maré D, Morisky DE, Chen YMA. Medication-adherence predictors among patients with tuberculosis or human immunodeficiency virus infection in Burkina Faso. J Microbiol Immunol Infect. 2014;47(3):222–32.CrossRefPubMedGoogle Scholar
  56. 56.
    Medley A, Seth P, Pathak S, et al. Alcohol use and its association with HIV risk behaviors among a cohort of patients attending HIV clinical care in Tanzania, Kenya, and Namibia. AIDS Care. 2014;26(10):1288–97.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Morojele NK, Kekwaletswe CT, Nkosi S. Associations between alcohol use, other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. AIDS Behav. 2014;18(3):519–24.CrossRefPubMedGoogle Scholar
  58. 58.
    Nachega JB, Morroni C, Chaisson RE, et al. Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient Prefer Adher. 2012;6:887–91.CrossRefGoogle Scholar
  59. 59.
    Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, et al. Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: a case-control study. J Affect Disord. 2013;145(2):221–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Nduaguba SO, Soremekun RO, Olugbake OA, Barner JC. The relationship between patient-related factors and medication adherence among Nigerian patients taking highly active anti-retroviral therapy. Afr Health Sci. 2017;17(3):738–45.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Negash T, Ehlers V. Personal factors influencing patients’ adherence to ART in Addis Ababa, Ethiopia. J Assoc Nurses AIDS Care JANAC. 2013;24(6):530–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Newman J, Iriondo-Perez J, Hemingway-Foday J, et al. Older adults accessing HIV care and treatment and adherence in the IeDEA Central Africa cohort. AIDS Res Treat. 2012;2012:725713.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Pefura-Yone EW, Soh E, Kengne AP, Balkissou AD, Kuaban C. Non-adherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria. J Infect Public Health. 2013;6(4):307–15.CrossRefPubMedGoogle Scholar
  64. 64.
    Peltzer K, Friend-du Preez N, Ramlagan S, Anderson J. Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa. BMC Public Health. 2010;10:111.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Ramlagan S, Peltzer K, Ruiter RAC, Barylski NA, Weiss SM, Sifunda S. Prevalence and factors associated with fixed-dose combination antiretroviral drugs adherence among HIV-positive pregnant women on Option B treatment in Mpumalanga Province, South Africa. Int J Environ Res Public Health. 2018;15(1):E161.CrossRefPubMedGoogle Scholar
  66. 66.
    Ransome Y, Mayer KH, Tsuyuki K, et al. The role of religious service attendance, psychosocial and behavioral determinants of antiretroviral therapy (ART) adherence: results from HPTN 063 cohort study. AIDS Behav. 2019;23(2):459–74.CrossRefPubMedGoogle Scholar
  67. 67.
    Sangeda EZ, Mosha F, Aboud S, et al. Predictors of non-adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug Healthc Patient Saf. 2018;10:79–88.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Shumba C, Atuhaire L, Imakit R, Atukunda R, Memiah P. Missed doses and missed appointments: adherence to ART among adult patients in Uganda. ISRN AIDS. 2013;2013:270914.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. Drug Alcohol Depend. 2016;167:103–11.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Sileo KM, Kitzito W, Wanyenze RK, et al. Substance use and its effect on antiretroviral treatment adherence among male fisherfolk living with HIV/AIDS in Uganda. PLoS ONE. 2019;14(6):e0216892.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Teshome W, Belayneh M, Moges M, Endriyas M, Mekonnen E, Ayele S, et al. Who takes the medicine? Adherence to antiretroviral therapy in Southern Ethiopia. Patient Prefer Adher. 2015;9:1531–7.CrossRefGoogle Scholar
  72. 72.
    Veld DH, Pengpid S, Colebunders R, Skaal L, Peltzer K. High-risk alcohol use and associated socio-demographic, health and psychosocial factors in patients with HIV infection in three primary health care clinics in South Africa. Int J STD AIDS. 2017;28(7):651–9.CrossRefGoogle Scholar
  73. 73.
    Wandera B, Tumwesigye NM, Nankabirwa JI, et al. Alcohol consumption among HIV-infected persons in a large urban HIV clinic in Kampala Uganda: a constellation of harmful behaviors. PloS ONE. 2015;10(5):e0126236.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Wandera B, Tumwesigye NM, Nankabirwa JI, et al. Hazardous alcohol consumption is not associated with CD4+ T-cell count decline among PLHIV in Kampala Uganda: a prospective cohort study. PloS ONE. 2017;12(6):e0180015.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Weiser SD, Palar K, Frongillo EA, et al. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. AIDS. 2014;28(1):115–20.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Yaya I, Landoh DE, Saka B, et al. Predictors of adherence to antiretroviral therapy among people living with HIV and AIDS at the regional hospital of Sokodé, Togo. BMC Public Health. 2014;14:1308.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    WHO Assist Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRefGoogle Scholar
  78. 78.
    Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804.CrossRefPubMedGoogle Scholar
  79. 79.
    Bush K, Kivlahan, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMedGoogle Scholar
  80. 80.
    Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA. 1984;252(14):1905–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.PubMedGoogle Scholar
  82. 82.
    Buscher A, Hartman C, Kallen MA, Giordano TP. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naïve, HIV patients. HIV Clin Trials. 2011;12(5):244–54.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18(7):853–61.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.CrossRefGoogle Scholar
  85. 85.
    Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13(4):227–36.CrossRefPubMedGoogle Scholar
  86. 86.
    Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP, MASH Research Team. Behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. AIDS Behav. 2017;21(Suppl 2):126–43.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(1):S23.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Papas RK, Sidle JE, Gakinya BN, et al. Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction. 2011;106(12):2156–66.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Senyonyi RM, Underwood LA, Suarez E, Musisi S, Grande TL. Cognitive behavioral therapy group intervention for HIV transmission risk behavior in perinatally infected adolescents. Health. 2012;4(12):1334–45.CrossRefGoogle Scholar
  90. 90.
    Wandera B, Tumwesigye NM, Nankabirwa JI, et al. Efficacy of a single, brief alcohol reduction intervention among men and women living with HIV/AIDS and using alcohol in Kampala, Uganda: a randomized trial. J Int Assoc Provid AIDS Care. 2017;16(3):276–85.CrossRefPubMedGoogle Scholar
  91. 91.
    Bachanas P, Kidder D, Medley A, et al. Delivering prevention interventions to people living with HIV in clinical care settings: results of a cluster randomized trial in Kenya, Namibia, and Tanzania. AIDS Behav. 2016;20(9):2110–8.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Emenyonu NI, Fatch R, Muyindike WR, Kekibiina A, Woolf-King S, Hahn JA. Randomized study of assessment effects on alcohol use by persons with HIV in rural Uganda. J Stud Alcohol Drugs. 2017;78(2):296–305.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Edelman EJ, Hansen NB, Cutter CJ, et al. Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics. Addict Sci Clin Pract. 2016;11(1):1.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    World Health Organization. Global strategy to reduce the harmful use of alcohol. Geneva: World Health Organization; 2010.Google Scholar
  95. 95.
    Siegfried N, Parry C. Do alcohol control policies work? An umbrella review and quality assessment of systematic reviews of alcohol control interventions (2006–2017). PloS ONE. 2019;14(4):e0214865.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Sundström C, Blankers M, Khadjesari Z. Computer-based interventions for problematic alcohol use: a review of systematic reviews. Int J Behav Med. 2017;24(5):646–58.CrossRefPubMedGoogle Scholar
  97. 97.
    Gordon S, Rotheram-Borus MJ, Skeen S, Parry C, Bryant K, Tomlinson M. Research priorities for the intersection of alcohol and HIV/AIDS in low and middle income countries: a priority setting exercise. AIDS Behav. 2017;21(Suppl 2):262–73.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Schroder KEE, Carey MP, Vanable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med. 2003;26(2):104–23.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Alcaide ML, Ramlagan S, Rodriguez VJ, et al. Self-report and dry blood spot measurement of antiretroviral medications as markers of adherence in pregnant women in rural South Africa. AIDS Behav. 2017;21(7):2135–40.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Hahn JA, Bwana MB, Javors MA, Martin JN, Emenyonu NI, Bangsberg DR. Biomarker testing to estimate under-reported heavy alcohol consumption by persons with HIV initiating ART in Uganda. AIDS Behav. 2010;14(6):1265–8.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Morris C, Levine B, Goodridge G. Three-country assessment of alcohol-HIV related policy and programmatic responses in Africa. Afr J Drug Alcohol Stud. 2006;5:169–84.Google Scholar
  102. 102.
    Ioannidis JPA, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.International Clinical Research Center, Department of Global HealthUniversity of WashingtonSeattleUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  3. 3.Department of PsychologyUniversity of WashingtonSeattleUSA
  4. 4.School of Public HealthBrown UniversityProvidenceUSA

Personalised recommendations